XML 58 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:    
Research and development $ 83,215 $ 71,255
General and administrative 16,008 15,263
Goodwill impairment (see Note 2) 0 32,970
Total operating expenses 99,223 119,488
Loss from operations (99,223) (119,488)
Other income (expense):    
Interest income 3,075 1,041
Other income (expense), net 2,536 (1,960)
Total other income (expense), net 5,611 (919)
Net loss $ (93,612) $ (120,407)
Net loss per share, basic (in USD per share) $ (2.11) $ (3.78)
Net loss per share, diluted (in USD per share) $ (2.11) $ (3.78)
Weighted-average common shares outstanding, basic (in shares) 44,320,050 31,819,006
Weighted-average common shares outstanding, diluted (in shares) 44,320,050 31,819,006